JAK1 inhibition represents a good therapeutic strategy for patients suffering from significant pruritus and patients with an intense itch that does not respond to IL-4 receptor inhibitors, IL-13 inhibitors, and IL-31 receptor inhibitors [50]. This evidence concerns the gene IL13 and Pruritus.